Abstract:Oral premalignant lesions (OPLs) are related to tobacco use and mark individuals at high risk for oral cancer development. Increased mutagen sensitivity as measured by an in vitro mutagen challenge assay has been shown to be a risk factor for upper aerodigestive tract cancers. In this case control study, we used two assays with mutagens relevant to tobacco exposure (benzo[a]pyrene diol epoxide (BPDE) and bleomycin) to see whether sensitivity to these mutagens could be used as biomarkers for assessing risk of premalignant lesions. Furthermore, we evaluated whether 3p21.3 is a molecular target of BPDE damage in lymphocytes of patients with OPLs. There were 82 patients with OPLs and 89 healthy controls frequency matched to the cases on age, sex, ethnicity, and smoking status. These subjects' lymphocytes were treated in two separate experiments with either 2 microM BPDE for 24 h or 0.03 units/ml bleomycin for 5 h, and the frequency of induced chromatid breakage in Giemsa-stained preparations was determined. BPDE-induced 3p21.3 aberrations were scored by fluorescent in situ hybridization technique in 1000 interphases/sample. We found that the mean BPDE-induced chromatid breaks per cell were higher in cases than controls (1.05 +/- 0.40 and 0.55 +/- 0.27, respectively; P < 0.01). Similar results were evident with bleomycin-induced chromatid breaks per cell (0.78 +/- 0.37 and 0.57 +/- 0.31, respectively; P < 0.01). After adjusting for age, sex, ethnicity, and smoking status, significantly elevated odds ratios (95% confidence interval) for OPL risk were noted for BPDE sensitivity [12.96 (5.51, 30.46)] and bleomycin sensitivity [3.33 (1.64, 6.77)]. When subjects were categorized into quartiles of the number of breaks per cell, a dose response was observed for both assays. The adjusted odds ratios for subjects with increasing numbers of breaks per cell in quartiles were 2.34, 9.14, and 54.04 for BPDE sensitivity and 1.92, 3.33, and 7.15 for bleomycin sensitivity, respectively. Subjects sensitive to both mutagens had a 50-fold increased risk for OPLs. In addition, there were significantly more BPDE-induced chromosome aberrations at the 3p21.3 locus in cases (51.13/1000) than in controls (40.93/1000; P < 0.0001). However, no such difference was observed for 3q13, a control locus. BPDE-induced 3p21.3 aberrations were associated with an elevated risk for OPLs of 6.08 (2.57, 14.4). The degree of BPDE sensitivity at 3p21.3 and risk for OPLs increased in a dose-dependent manner. In summary, BDPE sensitivity and bleomycin sensitivity appear to be individually and jointly associated with elevated risk of OPLs. Furthermore, 3p21.3 may be a molecular target of BPDE in OPLs. This is the first study to examine mutagen sensitivity in a premalignant condition. The next step is to correlate these findings in surrogate (lymphocyte) tissue with molecular events in the target tissue.

From Risk to Survival: Chromosome 3p Aberrations in Renal Cell Carcinoma

BPDE Induced Lymphocytic Chromosome 3p Deletions May Predict Renal Cell Carcinoma Risk

BPDE‐induced Lymphocytic 3p21.3 Aberrations May Predict Head and Neck Carcinoma Risk

Benzo[a]pyrene Diol Epoxide-Induced 3p21.3 Aberrations and Genetic Predisposition to Lung Cancer.

Genome-wide Profiling of Chromosomal Aberrations in Renal Cell Carcinoma Using High-Density Single Nucleotide Polymorphism Arrays

Loss of Heterozygosity on Chromosome 3p in Breast Cancer and Precancerous Lesion

Comprehensive Genomic Profiling in Chinese Patients with Clear Cell Renal Cell Carcinoma.

Genome-Wide Profiling Of Chromosomal Alterations In Renal Cell Carcinoma Using High-Density Single Nucleotide Polymorphism Arrays

Chromosome Instability in Lymphocytes: a Potential Indicator of Predisposition to Oral Premalignant Lesions.

Benzo[a]pyrene Diol Epoxide‐induced 9p21 Aberrations Associated with Genetic Predisposition to Bladder Cancer

Specific Chromosome Aberrations in Peripheral Blood Lymphocytes Are Associated with Risk of Bladder Cancer.

Loss of Heterozygosity on Chromosome 3p in Thyroid Tumors

Loss of heterozygosity at chromosome 3P14-24 in patients with breast cancer

Loss of heterozygosity on chromosome 3p, 7q, and 17p is associated with lymph node involvement and poor prognosis in human breast cancer

Chromosome 3p gene alterations as biomarkers for immunocombinations in metastatic renal cell carcinoma: A hypothesis-generating analysis

Benzo(a)pyrene diol epoxide-induced chromosome 9p21 aberrations are associated with increased risk of bladder cancer.

Alterations on Chromosome 3 in Endemic and Nonendemic Nasopharyngeal Carcinoma

Timing the Landmark Events in the Evolution of Clear Cell Renal Cell Cancer: TRACERx Renal

High APOBEC3B expression is a predictor of recurrence in patients with low-risk clear cell renal cell carcinoma

Risk assessment of renal cell carcinoma using alkaline comet assay.

Multicolor FISH Mapping of YAC Clones in 3p14 and Identification of a YAC Spanning Both FRA3B and the T(3;8) Associated with Hereditary Renal Cell Carcinoma.